Dalakas M C, Aksamit A J, Madden D L, Sever J L
Arch Neurol. 1986 Sep;43(9):933-5. doi: 10.1001/archneur.1986.00520090061018.
Recombinant leukocyte alpha 2-interferon (with greater than 98% purity) was evaluated in a pilot treatment in six patients with amyotrophic lateral sclerosis and one patient with slowly progressive postpoliomyelitis motor neuron disease. Interferon, administered subcutaneously in doses of 2 million units three times per week for four months, was ineffective in improving, arresting, or slowing the pace of progression in all the patients who were followed up for ten to 14 months after the end of therapy.
重组白细胞α2干扰素（纯度大于98%）在对6例肌萎缩侧索硬化症患者和1例缓慢进展的小儿麻痹后遗症运动神经元病患者的初步治疗中进行了评估。干扰素以每周三次、每次200万单位的剂量皮下注射，持续四个月，在治疗结束后对所有随访10至14个月的患者中，在改善、阻止或减缓疾病进展速度方面均无效。
